Skip to content
Biodatica
Start free

Janssen Research & Development, LLC

Clayton, Arizona

OncologyPhase IIIListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

95no change

Momentum 95 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Dec 26, 2024

    Depressive Disorder, Major · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

    ClinicalTrials.gov · NCT06785012 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Dec 4, 2024

    Multiple Myeloma · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

    ClinicalTrials.gov · NCT06768489 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Jul 23, 2024

    Carcinoma, Non-Small-Cell Lung · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

    ClinicalTrials.gov · NCT06532032 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Mar 29, 2023

    Relapsed or Refractory Multiple Myeloma · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT05572515 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Jan 17, 2020

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

    ClinicalTrials.gov · NCT04235270 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Dec 17, 2019

    Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants

    ClinicalTrials.gov · NCT04185051 (opens the source filing in a new tab)

  7. Trial

    PHASE2 registered

    Feb 14, 2017

    Myelodysplastic Syndromes · COMPLETED · sponsor: Janssen Research & Development, LLC · Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

    ClinicalTrials.gov · NCT03011034 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources